科伦药业跌2.00%，成交额2.63亿元，主力资金净流出4999.54万元

Core Viewpoint - Kelong Pharmaceutical's stock has experienced a decline, with a current price of 29.87 yuan per share and a market capitalization of 47.734 billion yuan, reflecting a challenging financial performance in recent months [1] Financial Performance - For the period from January to September 2025, Kelong Pharmaceutical reported a revenue of 13.277 billion yuan, a year-on-year decrease of 20.92%, and a net profit attributable to shareholders of 1.201 billion yuan, down 51.41% year-on-year [2] - The company's stock price has increased by 1.93% year-to-date, but has seen declines of 5.74% over the last five trading days, 13.22% over the last 20 days, and 20.27% over the last 60 days [1] Shareholder Information - As of September 30, 2025, Kelong Pharmaceutical had 37,100 shareholders, an increase of 8.35% from the previous period, with an average of 35,200 circulating shares per shareholder, a decrease of 7.70% [2] - The company has distributed a total of 6.898 billion yuan in dividends since its A-share listing, with 3.587 billion yuan distributed in the last three years [3] Institutional Holdings - Among the top ten circulating shareholders as of September 30, 2025, notable changes include a decrease in holdings by major funds such as China Europe Medical Health Mixed A and Industrial Bank Frontier Medical Stock A [3]